The BCR-ABL35INS insertion/truncation mutant is kinase-inactive and does not contribute to tyrosine kinase inhibitor resistance in chronic myeloid leukemia.
about
Current developments in molecular monitoring in chronic myeloid leukemiaPhosphoproteomics data classify hematological cancer cell lines according to tumor type and sensitivity to kinase inhibitorsClonal distribution of BCR-ABL1 mutations and splice isoforms by single-molecule long-read RNA sequencing.All tyrosine kinase inhibitor-resistant chronic myelogenous cells are highly sensitive to ponatinib.Nickel pyrithione induces apoptosis in chronic myeloid leukemia cells resistant to imatinib via both Bcr/Abl-dependent and Bcr/Abl-independent mechanisms.Multicenter phase II clinical trial of nilotinib for patients with imatinib-resistant or -intolerant chronic myeloid leukemia from the East Japan CML study group evaluation of molecular response and the efficacy and safety of nilotinib.BCR-ABL1 kinase domain mutations: methodology and clinical evaluation.Approaches for measuring signalling plasticity in the context of resistance to targeted cancer therapies.Compound mutations in BCR-ABL1 are not major drivers of primary or secondary resistance to ponatinib in CP-CML patients.Platinum pyrithione induces apoptosis in chronic myeloid leukemia cells resistant to imatinib via DUB inhibition-dependent caspase activation and Bcr-Abl downregulation.Ponatinib as a Valid Alternative Strategy in Patients with Blast Crisis-Chronic Myeloid Leukemia Not Eligible for Allogeneic Stem Cells Transplantation and/or Conventional Chemotherapy: Report of a Case.Resistance to imatinib in patients with chronic myelogenous leukemia and the splice variant BCR-ABL1(35INS).Rapid identification of compound mutations in patients with Philadelphia-positive leukaemias by long-range next generation sequencing.Persistent detection of alternatively spliced BCR-ABL variant results in a failure to achieve deep molecular response.
P2860
Q28066148-D6DFCE69-5BB4-427B-A037-AC06DC896B9EQ30620482-4F394743-DA2A-4C1A-8BE4-1889869EF9D2Q35104426-5BF18F4D-A5CE-416A-926B-1005A9CD7F3AQ36926106-8ADBADF3-5160-48F2-9CB5-883192E76819Q37440054-10064781-9026-4871-A79F-F4366F9F6EAAQ37714981-00F9A041-E6FD-41C0-AF89-C38583532E64Q37974490-680B07F0-645C-4DA1-B3C0-370AA5DA48DAQ38238607-ABB3307F-8CC5-4E3D-8F3B-F85533156A0BQ38562354-F517CF58-7253-4874-95B4-7B98E7F40983Q41335233-8041280D-CC85-4259-84CD-4FBDAD755AE6Q41613498-8A0C5A03-6BD2-4165-AACE-AE9DA43B3F7FQ41851898-9924B666-1138-4DA4-AF73-0ADF9D51B642Q41938173-B0FB06A4-92FF-4715-9D30-5CD2A98B567FQ45348850-28F1C44C-410A-48AD-BA83-7CFE175378D8
P2860
The BCR-ABL35INS insertion/truncation mutant is kinase-inactive and does not contribute to tyrosine kinase inhibitor resistance in chronic myeloid leukemia.
description
2011 nî lūn-bûn
@nan
2011 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
The BCR-ABL35INS insertion/tru ...... e in chronic myeloid leukemia.
@ast
The BCR-ABL35INS insertion/tru ...... e in chronic myeloid leukemia.
@en
type
label
The BCR-ABL35INS insertion/tru ...... e in chronic myeloid leukemia.
@ast
The BCR-ABL35INS insertion/tru ...... e in chronic myeloid leukemia.
@en
prefLabel
The BCR-ABL35INS insertion/tru ...... e in chronic myeloid leukemia.
@ast
The BCR-ABL35INS insertion/tru ...... e in chronic myeloid leukemia.
@en
P2093
P2860
P1433
P1476
The BCR-ABL35INS insertion/tru ...... e in chronic myeloid leukemia.
@en
P2093
Amie S Corbin
Anupriya Agarwal
Christopher A Eide
Huihong You
Julie Toplin
Lauren T Adrian
Matthew S Zabriskie
Michael W Deininger
Stephane Wong
P2860
P304
P356
10.1182/BLOOD-2011-05-349191
P407
P577
2011-09-08T00:00:00Z